Loading
A phase 1/2 trial of gemcitabine, capecitabine and sintilimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.
Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer. is a phase 1/2, interventional study registered as NCT06888674 by Zhejiang University, with a registry enrolment figure of 60 participants, started 2025-04-01 and due to reach its primary completion in 2027-04-01. Interventions recorded: individualized anti-tumor new antigen iNeo-Vac-R01 injection; Gemcitabine + Capecitabine; Sintilimab injection. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: Occurence and frequence of AE and SAE. Pancreatic eligibility wording from the registry: "* Diagnosed with resectable pancreatic cancer as assessed per the 2024 NCCN Clinical Practice Guidelines and willing to undergo radical surgery;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Sintilimab, Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine, Cytotoxic chemotherapy and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Capecitabine, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Capecitabine, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.
Shares Sintilimab, Pancreatic cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy, Immune checkpoint inhibitors and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Capecitabine, Pancreatic cancer trials open today (registry snapshot and UK sites), Gemcitabine and the tag pancreatic-deep-dive.